Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DaeMon-Plus: Biweekly Docetaxel, Oxaliplatin, and 5-FU in Advanced Gastric Cancer
NCT02289378Phase 2Unknown
- Sponsor
- The Sixth Affiliated Hospital of Sun Yat-Sen University
- Start
- Nov 2014
- Primary completion
- Oct 2016
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, oxaliplatin and fluorouracil in gastric adenocarcinoma, sponsored by The Sixth Affiliated Hospital of Sun Yat-Sen University. Primary endpoint: Progression-free survival at 2 years. Status: unknown.
02
Drugs
docetaxeloxaliplatinfluorouracil
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on NCT02289378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02289378.